MedPath

The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)

Not yet recruiting
Conditions
HIV Seropositivity
Blood Disease
Cancer
Interventions
Diagnostic Test: HIV Ag +Ab Assay Kit (Sysmex)
Registration Number
NCT05983536
Lead Sponsor
Qianfoshan Hospital
Brief Summary

To evaluate the anti-interference and specificity of HIV Ag +Ab Assay Kit (Sysmex) for the detection of HIV antigens and antibodies.

Detailed Description

First,HIV Ag +Ab Assay Kit (Sysmex)Assay Kit (Sysmex) was used to detect HIV antigens and antibodies in the serum of patients with tumor and blood diseases, and then confirmed by using the gold standard for HIV diagnosis,human immunodeficiency virus (HIV type 1+2) antibody assay kit (immunoimprinting). The specificity of HIV Ag +Ab Assay Kit (Sysmex) for HIV assay in patients with tumor and hematological diseases was calculated.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
1200
Inclusion Criteria
  • Clinical diagnosis of tumor Disease or blood disease
  • Blood samples must meet the test requirements
Exclusion Criteria
  • N/A

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with blood diseasesHIV Ag +Ab Assay Kit (Sysmex)Bone marrow aspiration and biopsy confirmed the blood disease
Cancer patientsHIV Ag +Ab Assay Kit (Sysmex)Cancer patints that confirmed by pathological examination
Primary Outcome Measures
NameTimeMethod
The HIV Ab/Ag resultsthrough study completion, an average of 1.5 year

The HIV Ab/Ag results generated using HIV Ag +Ab Assay Kit (Sysmex) and the gold standard method for HIV test. The results will be recoreded seperately.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath